Butane-1-sulfonic acid 3-((R)-2-tert-butoxycarbonylamino-propyl)-1H-indol-7-yl ester | 820216-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Butane-1-sulfonic acid 3-((R)-2-tert-butoxycarbonylamino-propyl)-1H-indol-7-yl ester
• CAS: 820216-31-7
• 化学式: C₂₀H₃₀N₂O₅S
• 分子量: 410.535
• InChiKey: DOIARIJMSSIHHO-CQSZACIVSA-N

物化性质

• 沸点：
  601.9±55.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.13
• 重原子数：
  28.0
• 可旋转键数：
  8.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  97.49
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  Butane-1-sulfonic acid 3-((R)-2-tert-butoxycarbonylamino-propyl)-1H-indol-7-yl ester 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 Butane-1-sulfonic acid 3-((R)-2-amino-propyl)-1H-indol-7-yl ester
  参考文献：
  名称：

  Tryptamine-based human β3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring

  摘要：

  A series of tryptamine-based 2-thiophenesulfonamide derivatives were prepared and their agonistic activity for the beta-adrenergic receptors (ARs) was evaluated. Compound 54, containing 7-methanesulfonyloxy tryptamine, was found to be a highly potent beta(3)-AR agonist (EC50 = 0.21 nM, IA = 97%) with excellent selectivity for the beta(3)-AR over the beta(1)- and beta(2)-ARs (210- and 86-fold, respectively). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.035
• 作为产物：
  描述：

  (R)-3-(2-aminopropyl)-7-benzyloxyindole 在 palladium on activated charcoal TEA 、 甲酸铵 作用下， 以 甲醇 、 二氯甲烷 、 氯仿 为溶剂， 生成 Butane-1-sulfonic acid 3-((R)-2-tert-butoxycarbonylamino-propyl)-1H-indol-7-yl ester
  参考文献：
  名称：

  Tryptamine-based human β3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring

  摘要：

  A series of tryptamine-based 2-thiophenesulfonamide derivatives were prepared and their agonistic activity for the beta-adrenergic receptors (ARs) was evaluated. Compound 54, containing 7-methanesulfonyloxy tryptamine, was found to be a highly potent beta(3)-AR agonist (EC50 = 0.21 nM, IA = 97%) with excellent selectivity for the beta(3)-AR over the beta(1)- and beta(2)-ARs (210- and 86-fold, respectively). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.035